Abstract |
KOGENATE Bayer ( rFVIII-FS) with Bio-Set is designed to prevent patient contact with exposed needles during recombinant factor VIII reconstitution. This postmarketing surveillance study evaluated patient satisfaction before and after switching to the new Bio-Set reconstitution method. Male children and adults with haemophilia A were enrolled from nine European countries. A preference questionnaire was administered to patients after Bio-Set training and at the end of the observation period (> or =20 exposure days or 3 months). Physician assessments of patient compliance and satisfaction were conducted at the end of the observation period. Patients (N = 306) received a mean +/- SD of 28 +/- 23 infusions of rFVIII-FS with Bio-Set. A majority of patients (82%) preferred the Bio-Set method, with domain scores for ease of use, safety from needlesticks, and speed of reconstitution being highest after training and at the end of the observation period. The Bio-Set method received higher mean scores than previous reconstitution methods for worry/safety and ease/confidence domains at both time points. Physician-reported patient compliance with the Bio-Set method was similar or greater compared with the previous method for 94% of the patients, with physicians reporting that 92% of the patients were satisfied or very satisfied with Bio-Set. Thirteen adverse events (AEs) occurred in nine patients, and five serious AEs occurred in five patients; none was related to rFVIII-FS. No de novo or recurrent inhibitor development was observed during the observation period. rFVIII-FS with Bio-Set was well tolerated and well accepted by haemophilia A patients, which may improve treatment compliance.
|
Authors | N Vidovic, R Musso, R Klamroth, M M Enriquez, K Achilles |
Journal | Haemophilia : the official journal of the World Federation of Hemophilia
(Haemophilia)
Vol. 16
Issue 1
Pg. 66-71
(Jan 2010)
ISSN: 1365-2516 [Electronic] England |
PMID | 19878338
(Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Recombinant Proteins
- F8 protein, human
- Factor VIII
|
Topics |
- Adolescent
- Adult
- Aged
- Child
- Child, Preschool
- Factor VIII
(administration & dosage, therapeutic use)
- Hemophilia A
(drug therapy)
- Home Infusion Therapy
(methods)
- Humans
- Infant
- Male
- Medication Adherence
- Middle Aged
- Patient Satisfaction
- Product Surveillance, Postmarketing
- Recombinant Proteins
(administration & dosage, therapeutic use)
- Surveys and Questionnaires
- Young Adult
|